You-Gui pills promote nerve regeneration by regulating netrin1, DCC and Rho family GTPases RhoA, Racl, Cdc42 in C57BL/6 mice with experimental autoimmune encephalomyelitis

• Published in: Journal of ethnopharmacology 2016-07, Vol.187, p.123-133
• Main Authors: Ji, Xiaomin, Liu, Haolong, An, Chen, Wang, Yongqiang, Zhao, Hui, Zhang, Qiuxia, Li, Ming, Qi, Fang, Chen, Zhenzhen, Wang, Xiujuan, Wang, Lei
• Format: Article
• Language: English
• Subjects: Animals; Brain - drug effects; Brain - pathology; Brain - ultrastructure; DCC Receptor; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Encephalomyelitis, Autoimmune, Experimental - metabolism; Encephalomyelitis, Autoimmune, Experimental - pathology; Experimental autoimmune encephalomyelitis; Female; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Myelin-Oligodendrocyte Glycoprotein; Nerve Growth Factors - genetics; Nerve Growth Factors - metabolism; Nerve regeneration; Nerve Regeneration - drug effects; Netrin-1; Netrin1/DCC; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Peptide Fragments; Phytotherapy; Receptors, Cell Surface - genetics; Receptors, Cell Surface - metabolism; Rho family GTPases RhoA, Rac1 and Cdc42; rho GTP-Binding Proteins - genetics; rho GTP-Binding Proteins - metabolism; RNA, Messenger - metabolism; Spinal Cord - drug effects; Spinal Cord - pathology; Spinal Cord - ultrastructure; Tablets; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; You-Gui Pills
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2016.04.025

You-Gui pills (YGPs) are an effective traditional Chinese formula being used clinically for the treatment of multiple sclerosis (MS). Previous studies demonstrated that YGPs exerted the potent neuroprotective effects in murine models of experimental autoimmune encephalomyelitis (EAE), which is an equivalent animal model for multiple sclerosis (MS). However, the mechanism of YGPs functions remained unclear. The aim of this study was to evaluate the therapeutic effect of YGPs in MOG35–55-induced EAE mice and to further elucidate the underlying molecular mechanism. Methods: Female C57BL/6 mice were divided into six groups, including the non-treated EAE model, prednisone acetate- and 1.2, 2.4 or 4.8g/kg YGPs-treated EAE groups, and a normal control group. The EAE model was established by injecting the mice subcutaneously with MOG35–55 antigen. The body weights were measured and the neurological functions were scored in each group. The pathology and morphology of the brain and spinal cord was examined. The expression of MAP-2 was detected by immunofluorescent staining. The levels of netrin1, DCC, RhoA, Rac1, and Cdc42 were assayed by immunohistochemistry, qRT-PCR and Western blot on day 40 post-immunization (PI). YGPs treatments significantly reduced neurological function scores in EAE mice, where the inflammatory infiltration was reduced and the axon and myelin damage in both brain and spinal cord was alleviated. In the brain and spinal cord tissues, YGPs increased the expression of neuronal factors MAP-2, netrin1 and DCC. The expression of Rac1 and Cdc42 were increased, while RhoA was reduced following YGPs treatments. Our results demonstrated that YGPs exhibited a neuroprotective effect on promoting nerve regeneration at the brain and spinal cord in EAE mice induced by MOG35–55. Netrin1, DCC and the Rho family GTPases of RhoA, Racl, Cdc42 were involved in mediating the effects of YGPs on nerve regeneration. [Display omitted]